Safety and Efficacy
- Extensive data, including randomized controlled trial data and FDA-reviewed studies, support Impella® safety and efficacy.1,2,7
- Impella 2.5® and Impella CP® maintain patient hemodynamics which may allow for more complete revascularization and reduction in major adverse coronary and cerebrovascular events (MACCE).8
- Impella heart pumps are associated with reduction of kidney injury during high-risk PCI.3
- PROTECT III, the most contemporary data, continues to show a reduction in MACCE with Impella2
All MACCE to 90 Days
Complete Revascularization Associated with Improved Outcomes
Benefits in high-risk acute coronary syndrome (ACS) patients at 1 year4
- 71% risk reduction in all-cause death
- 27% risk reduction in major adverse cardiovascular events (MACE)
- 41% risk reduction in myocardial infarction (MI)
Benefits in high-risk STEMI patients at 3 years5
- 26% risk reduction in cardiovascular (CV) Death/MI
- 47% risk reduction in CV Death/MI/Revascularization
Meta-analysis of benefits in 11 high-risk STEMI studies6
- 29% risk reduction in CV Death/MI
Protected PCI Improves Quality of Life
Clinical data demonstrate that Protected PCI improves quality of life by increasing ejection fraction, reducing NYHA class, reducing adverse events, and reducing acute kidney injury requiring dialysis.3,7,8
“PROTECT III clearly demonstrates how the evolution and adoption of Impella best practices can lead to an improvement in safety and MACCE.”
Ongoing and Upcoming Clinical Trials
PROTECT IV Randomized Controlled Trial
Ongoing trial to compare complete revascularization PCI with Impella to complete revascularization PCI without any planned hemodynamic support.
Resources from the Education Library
Clinical Dossier: Protected PCI with Impella
Features current clinical experience with Impella, clinical need for Impella in high-risk PCI, clinical evidence of safety and effectiveness of Impella Protected PCI, and more.
RESTORE EF: Ejection Fraction Improvement with Complete Revascularization
Mitul Patel, MD, reviews the findings of the RESTORE EF study and a successful case of improved ejection fraction with complete revascularization.
Improved Outcomes with Contemporary Practices in PROTECT III
Jeffrey Moses, MD, discusses the improved outcomes with contemporary practices seen in the PROTECT III study of Impella-supported high-risk PCI.
- Dixon, S.R., et al. (2009). JACC Cardiovasc Interv, 2(2), 91-96.
- Moses, J., et al. (2020). Presented at TCT Connect 2020.
- Flaherty, M.P., et al. (2017). Circ Res, 120(4), 692-700.
- Généreux, P., et al. (2012). J Am Coll Cardiol, 59(24).
- Mehta, S.R., et al. (2019). N Engl J Med, 381(15):, 1411-1421.
- Bainey, K.R., et al., (2020) JAMA Cardiol.
- O’Neill, W.W., et al. (2012). Circulation, 126(14), 1717-1727.
- Dangas, G.D., et al. (2014). Am J Cardiol, 113(2), 222-228.